 1945 |
Company predecessor, Glucose Corporation, instilled. |
|
|
|
| Oct. 1962 |
Company
reorganized as Sintong Chemical Industry Company, Limited
with $35 million paid-in capitalization as an integrated
local pharmaceutical producer.
|
|
|
1979 |
20ml
BFS filler machine procured marking the firm as a premiere
local SVP¡] small volume parenteral¡^producer.
|
|
|
|
| 1987 |
*
Paid-in capitalization upped to $200 million with IPO
completed and passed GMP¡]Good Manufacture Practice¡^inspection.
* Representation of Japan's Nikkiso hemodialysis equipment
as the agency embarked on the medical treatment equipment
and related field.
* Exports reaching Vietnam to excel Sintong in global
expansion.
* Full computerization inducted. |
|
|
| 1988 |
Launched
the first bio-equivalent test product in Taiwan, Ranidine,
formally certified by the Department of Health. |
|
|
| 1989 |
*
Addition of 20ml BFS filling machine.
* Investment in Taiwan Biotech Co., Ltd offering upstream
Active Pharmaceutical Ingredients (APIs). |
|
|
| 1990 |
*
Technical pact with the Japanese Eisai in jointly producing
Aminol-K and the presentation of many of its related
products.
* Joint development of transdermal delivery drug system
(TDDS) with an U.S.A. Pharmaceutical Development company.
|
|
|
| 1992 |
*
Accredited with Outstanding Award in the first Outstanding
Biotech Awards by the Ministry of Economic Affairs.
* Bestowed with a pilot new product R&D plan for
transdermal products sanctioned by the Ministry of Economic
Affairs' Bureau of Industrial Development.
|
|
|
|
| 1993 |
*
Accredited with an Outstanding Award by the ROC Biotech
Industry Development Council.
* Branch office launched at the Hsinchu Science-based
Industrial Park.
|
|
|
| 1994 |
*
Curie Chemicals and Pharmaceuticals Manufacturing
Co., Ltd's plant joined Taiwan Biotech's production
line in producing oral products.
* The addition of 10ml BFS filler machine.
* API plant certified by the U.S. Food & Drug
Administration. |
|
|
| 1995 |
Innovative
transdermal nicotine patch, Smokfree ,
debuted. |
|
|
|
| 1996 |
AnPo,
a labour inhibitors, debuted. |
|
|
| 1997 |
Export
of a 20ml BFS¡]Bill-Flow-Seal¡^to Japan began |
|
|
|
| 1998 |
* Reinvestments made at Huaneng Pharmaceutical Company in Mainland China.
* Dynamics Venture Capital formed in a move to integrate
the company's venture investments. |
|
|
| 1999 |
*
Represent the U.S. pharmaceutical company, Ocular
Sciences' contact lenses.
* Sales and marketing of respiratory system medical
equipment, began.
* Investments made to the U.S. company, Optics Corporation,
through which TBC's products started to export to
the U.S. |
 |
|
|
| 2001 |
*
Renamed as Taiwan Biotech Company, Limited.-
* Represent the U.S. pharmaceutical company, Cephalon's
Provigil-
a narcolepsy treatment solution.-
* Implemented and surpassed the cGMP phase-one review. |
|
|
|
| 2002 |
*
Biotech food manufactory launched at the Hsinchu
Science-based Industrial Park.
* Strategic alliance formed with Fresenius Medical
Care Corporation of Germany. |
|
|
| 2003 |
Implemented and surpassed the cGMP(II)-process validation review. |
|
|
| 2004 |
* Accredited with pharmaceutical technology research award in the third pharmaceutical technology research awards by the department of health executive yuan.
* Accredited with orphan drug research award in the third orphan drug research awards by the department of health executive yuan. |
|
|
| 2005 |
* Implemented and surpassed the cGMP(III)-computer validation review.
* Accredited with pharmaceutical technology research award in the forth pharmaceutical technology research awards by department of health executive yuan.
* Eye-Cept Rewetting Drops got FDA¡¦s approval of 510(k) for contact lens care products in USA.
* Purchasing the Kuan Yin plant of Fujisawa Pharmaceutical Co., Ltd in Taiwan.
* Acquired management authority of The Veterans Pharmaceutical Plant. |
|
